Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease
Author:
- 5 May 2015
- journal article
- review article
- Published by Wiley in Seminars in Dialysis
- Vol. 28 (4) , 363-369
Abstract
Bisphosphonates are medications which bind strongly to mineral. They are ingested by osteoclasts and inhibit an enzyme necessary for bone resorption. The gastrointestinal absorption is poor and the only method of excretion is renal. Therefore, in patients with CKD the body accumulates a higher percentage of a dose of bisphosphonate. These medications remain attached to bone mineral for many years. Although the primary action is to inhibit bone resorption, secondarily bone formation is also inhibited, and in patients with CKD bisphosphonate use often leads to adynamic bone. In some experimental models in animals, the bisphosphonates can inhibit vascular calcification but this effect has not been seen in humans. Intravenous bisphosphonates may cause renal damage but oral doses do not reduce creatinine clearance. In stage 3 CKD, in patients who still have normal PTH, calcium, and alkaline phosphatase, randomized trials show similar benefits as in patients without CKD. Data from stage 4 and 5 CKD are very limited and no clear benefit has been shown.Keywords
This publication has 53 references indexed in Scilit:
- Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal functionJournal of Pharmacological and Toxicological Methods, 2013
- Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancyJournal of Bone and Mineral Research, 2012
- Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patientsJournal of Bone and Mineral Research, 2010
- The link between bone and coronary calcifications in CKD-5 patients on haemodialysisNephrology Dialysis Transplantation, 2010
- Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failureKidney International, 2009
- Relationship between vascular calcification, arterial stiffness and bone mineral density in a cross‐sectional study of prevalent Australian haemodialysis patientsNephrology, 2009
- Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective StudyAmerican Journal of Kidney Diseases, 2008
- Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal womenKidney International, 2008
- Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosisBone, 2007
- Effect of Etidronic Acid on Arterial Calcification in Dialysis PatientsClinical Drug Investigation, 2006